Week in Review: Cannabis & Psychedelics Industry Highlights

LOS ANGELES – Two weeks that rewrote the rules. That is the most accurate way to characterize what the U.S. Сannabis and Psychedelics industries have experienced heading into the final days of April 2026. Federal policy shifted in ways operators spent decades petitioning for. Consumer product categories reshuffled. Capital crossed borders. Cannabis spread into areas that most industry veterans never expected to see commercialized. And underneath of it all, the numbers that kept climbing.

This edition of Week in Review covers the stories that moved markets, influenced strategy, and set the table for what comes next: from the most consequential federal regulatory decision in a generation to telling moves in retail consolidation, workforce planning, and genetics. We start where the industry’s attention is squarely focused.

1. The Federal Dam Breaks

Nothing in recent memory compares to what happened on April 23, 2026. Acting U.S. Attorney General Todd Blanche signed a Department of Justice order placing state-licensed medical Cannabis [along with FDA-approved Cannabis-based products} into Schedule III under the Controlled Substances Act. Simultaneously, the DEA announced an expedited administrative hearing set to begin June 29, 2026, to address the broader question of whether all Cannabis, including adult-use, follows the same path.

The DOJ order also directs Treasury to consider retrospective relief, meaning potential refunds for prior tax years. Industry advisors are urging caution on that front [amended returns should wait for formal IRS guidance] but the signal from the top of the federal government is unmistakable. The IRS and Treasury moved quickly to confirm they are preparing formal Tax Guidance on how rescheduling interacts with 280E, including a transition rule that will generally apply rescheduling relief to the full taxable year in which the DOJ’s final order becomes effective for qualifying business activities.

What the order does not do is equally important to understand. Adult-use Cannabis remains in Schedule I. Recreational operators see no immediate tax relief. Interstate commerce remains prohibited. And a formal administrative hearing with firm deadlines, concluding no later than July 15, 2026, will determine whether the rest of the market follows medical Cannabis into Schedule III. If that hearing produces a final rule on schedule, and litigation does not extend the calendar into 2027, the industry could see comprehensive rescheduling before year-end.

For now, the political signal is clear: medical first, adult-use second. The administration is proceeding surgically and on its own terms. Investors showed initial skepticism, with Cannabis stocks pulling back from early gains after the announcement – a reminder that the market has been burned by false starts before. But for operators inside qualifying state medical frameworks, this is the most significant federal development in the industry’s history.

The Oklahoma Law Review’s recent analysis arguing that 280E no longer applies post-rescheduling has added further legal momentum to that position, though formal IRS guidance remains the definitive word operators should wait for before restructuring their tax filings.

2. The White House Goes Further

Five days before the DOJ’s Cannabis rescheduling order, President Trump signed an executive order directing federal agencies to accelerate access to psychedelic drugs as medical treatments with a particular focus on veterans suffering from post-traumatic stress disorder (PTSD) and treatment-resistant depression (TRD).

The order is multi-pronged. The FDA has been directed to issue Commissioner’s National Priority Vouchers to psychedelic drugs that have received Breakthrough Therapy designations, eliminating red tape in the agency’s review process. The FDA and DEA have been instructed to establish a pathway for eligible patients to access investigational psychedelic compounds, including ibogaine, under Right to Try provisions. HHS has been directed to allocate $50 million through the ARPA-H program to match state investments in psychedelic research. And the Attorney General has been directed to initiate scheduling reviews for successfully completed Phase 3 psychedelic trials.

In direct response to the executive order, Compass Pathways opened a U.S. grant program for psychedelic therapy training, expanding the clinical infrastructure needed to support a sector that is moving from research to commercial reality faster than most observers anticipated. And AtaiBeckley reported expanded Phase 2a data for EMP-01 in social anxiety disorder, adding to a growing body of evidence that psychedelic-derived compounds can address conditions that have resisted conventional pharmacology.

3. Q1 2026 Sets the Revenue Baseline

The policy headlines do not exist in a vacuum. The commercial foundation underneath them is strong. Legal U.S. Cannabis markets generated over $6 billion in Q1 2026, affirming that consumer demand has not waited for federal reform to keep spending. A market producing that kind of revenue in a single quarter [under the full weight of 280E, banking restrictions, and Schedule I classification] is a market with considerable upside once those constraints begin to lift.

4. Consolidation Takes Shape in Cannabis

Glass House Brands and Vireo Health announced a combination of their California retail operations to form a new joint venture, pooling store footprints, operational infrastructure, and brand equity in a state where profitability has demanded efficiency gains that no single operator has been able to achieve alone.

LEEF Brands reached a deal to acquire Himalaya Vapor, expanding its retail and product portfolio in a transaction that reflects the ongoing consolidation of multi-format cannabis brands as the market rewards operators who can serve consumers across consumption method preferences.

In workforce development, Safe Harbor Financial is targeting the retirement planning gap in the Cannabis workforce, a dimension of industry infrastructure that rarely receives headline attention but matters enormously for long-term talent retention.

5. Hemp’s Regulatory Moment & Long-Term Market Potential

ATACH published an updated report on hemp regulations, providing the industry with a clearer picture of where the compliance framework stands following November 2025 legislative changes that adjust hemp-derived THC thresholds – changes that take effect in November 2026.

A new market analysis projects the industrial hemp market will exceed $7 billion by 2031, driven by construction materials, textile applications, and wellness product demand. This is a market that extends well beyond cannabinoids into hempcrete, fiber, and biocomposite materials that are attracting interest from sectors far outside traditional Cannabis.

6. International Expansion: Canadian Operators Look Outward

While domestic federal reform commanded the most attention, Canadian Cannabis operators continued executing international growth strategies that reflect a longer-term view of where the global market is heading.

Aurora Cannabis acquired Safari Flower to expand its EU-GMP certified production capacity, strengthening its position in the European medical Cannabis market, which continues to grow as member states advance their own regulatory frameworks.

Tilray Brands acquired Lyphe Group to expand its medical Cannabis reach in the United Kingdom, adding distribution and clinic network to its European commercial infrastructure.

On the financial performance front, Cannara Biotech reported Q2 2026 financial results  and Decibel Cannabis reported Q4 and full-year 2025 earnings, with both Canadian operators providing the market with performance benchmarks that reflect the ongoing tension between revenue growth and path-to-profitability pressures that characterize the mid-tier producer segment.

7. German Pharmacies Undercut the Black Market

In a data point that deserves more attention than it typically receives, German pharmacies are now offering Cannabis at prices below what consumers can obtain on the darknet. This is a meaningful milestone in any regulated market’s development, the point at which the legal channel becomes price-competitive with the illicit one.

8. Risks, Product Trends, Genetics & the Culture Side of the Business

The data on consumer product preferences confirmed what experienced retailers have known for some time: pre-rolls have officially surpassed flower as the top U.S. Cannabis category by unit sales.

Seed Junky Genetics announced the return of MINNTZ, a genetics collaboration with cultural resonance that reflects the increasingly important role of brand identity in a market where product differentiation is becoming harder to achieve through cannabinoid content alone. As the commodity layer of Cannabis markets compresses margins, genetics provenance and brand story become premium-tier differentiators.

In a category that speaks directly to the operational realities of the Cannabis industry, Relm Insurance launched a kidnap and ransom product specifically designed for Cannabis businesses. The product acknowledges a persistent reality: cash-intensive businesses operating in legal grey zones [under 280E, without banking access, and often without insurance coverage that mainstream carriers provide] face security risks that conventional commercial policies do not cover.

HCN Insight

The last fortnight represented something that veterans of the Cannabis & Psychedelics industries have spent careers working toward and often doubted would arrive: a federal government that is, for the first time in modern history, moving in the same direction as the market.

Schedule III for medical Cannabis is not federal legalization. The psychedelics executive order is not approval. And IRS guidance on 280E relief has not yet been formally issued. The work is far from finished. But the direction of travel has shifted in a way that is difficult to reverse, and the velocity of that shift [two major federal actions in five days] suggests that 2026 will be remembered as the year the regulatory environment began to catch up with commercial reality.

For operators, the priority right now is clarity over celebration. Understand which bucket your business falls into under the DOJ’s rescheduling order. Scenario-plan for both a full Schedule III outcome from the June 29 hearing and a delayed one. Monitor IRS guidance before restructuring tax filings. And recognize that the operators who will capture the most value from this moment are not the ones reacting to headlines, but the ones who have been building infrastructure (retail footprint, brand equity, workforce depth, international relationships) that scales under a lower-friction regulatory environment.

The $6 billion Q1 revenue baseline, the pre-roll category’s structural dominance, the cross-border acquisitions, the product innovation, the workforce investment – all of it points to an industry that has been running hard in difficult conditions. What changes now is that the conditions, for the first time, are beginning to improve.

The fight is not over yet.
It’s just the bell to end another round, but not the final one.